<DOC>
	<DOCNO>NCT00031733</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may make body build immune response . Combining vaccine therapy interleukin-12 either alum sargramostim may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness combine vaccine therapy interleukin-12 either alum sargramostim treat patient undergone surgery stage II , stage III , stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Interleukin-12 With Either Alum Sargramostim After Surgery Treating Patients With Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare immune reactivity patient resect stage IIB , IIC , III , IV melanoma vaccinate tyrosinase , gp100 , MART-1 peptide emulsify Montanide ISA-51 interleukin-12 either alum adjuvant sargramostim ( GM-CSF ) . OUTLINE : This randomize study . Patients stratify accord disease stage ( cutaneous stage IIB , IIC , III , IV v ocular mucosal stage III IV ) . Patients randomize 1 3 treatment arm . - Arm I : Patients receive vaccine tyrosinase:368-376 ( 370D ) /gp100:209-217 ( 210M ) /MART-1:26-27 ( 27L ) peptide emulsify Montanide ISA-51 ( ISA-51 ) , low-dose interleukin-12 ( IL-12 ) subcutaneously ( SC ) , alum adjuvant SC day 1 week 1 , 3 , 5 , 7 , 11 , 15 , 19 , 27 , 53 . - Arm II : Patients receive peptide vaccine emulsify ISA-51 , high-dose IL-12 SC , alum adjuvant SC day 1 week 1 , 3 , 5 , 7 , 11 , 15 , 19 , 27 , 53 . - Arm III : Patients receive peptide vaccine emulsify ISA-51 day 1 low-dose IL-12 SC sargramostim ( GM-CSF ) SC day 1-5 week 1 , 3 , 5 , 7 , 11 , 15 , 19 , 27 , 53 . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 60 patient ( 20 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<mesh_term>Aluminum sulfate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis stage IIB , IIC , III , IV cutaneous melanoma OR stage III IV ocular mucosal melanoma Resected render diseasefree HLAA2.1positive standard cytotoxicity assay Tumor tissue must available analysis gp100 stain tyrosinase MART1 expression immunohistochemistry Must positive least 1 antigen Failed , ineligible , refuse prior interferon alfa PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL No bleeding disorder Hepatic : Bilirubin great 2.0 mg/dL SGOT/SGPT great 2.5 time normal No coagulation disorder Hepatitis surface antigen B negative Hepatitis C negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : No major cardiovascular illness Pulmonary : No major respiratory illness Immunologic : No prior uveitis No prior autoimmune inflammatory eye disease No immune hemolytic anemia No active autoimmune disease Other : HIV negative No major gastrointestinal illness No malignancy within past 5 year except squamous cell skin cancer carcinoma situ cervix curatively treat least 30 day ago No major systemic infection ( e.g. , pneumonia sepsis ) No major medical illness No prior allergic reaction Montanide ISA51 alum adjuvant No requirement steroid therapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior tyrosinase:368376 ( 370D ) , gp100:209217 ( 210M ) , MART1:2635 ( 27L ) peptide Chemotherapy : At least 1 month since prior adjuvant chemotherapy disease No concurrent adjuvant chemotherapy Endocrine therapy : No concurrent steroids Radiotherapy : At least 1 month since prior radiotherapy disease No concurrent radiotherapy Surgery : See Disease Characteristics Other : At least 1 month since prior therapy , include adjuvant therapy , disease No concurrent therapy , include adjuvant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>iris melanoma</keyword>
	<keyword>ciliary body choroid melanoma , small size</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>